Endophthalmitis Cultures



Status:Completed
Conditions:Ocular
Therapuetic Areas:Ophthalmology
Healthy:No
Age Range:18 - Any
Updated:4/2/2016
Start Date:October 2011
End Date:August 2013
Contact:Stephen J Kim, MD
Email:stephen.j.kim@vanderbilt.edu
Phone:615-936-2020

Use our guide to learn which trials are right for you!

Prospective Surveillance of Patients With Endophthalmitis for Multi-antibiotic Resistance (PROSPER) Study

The intent of this surveillance study will be to obtain written permission from patients
with bacterial endophthalmitis in order to compare sterilization rates of their cultured
bacterial isolates to standard therapy (vancomycin and ceftazidime) versus combination
therapy with vancomycin, ceftazidime, and moxifloxacin.

Research hypothesis:

1. Cultured bacterial isolates will demonstrate faster in vitro sterilization rates with
combination treatment (vancomycin, ceftazidime, and moxifloxacin) compared to "standard
therapy" with vancomycin and ceftazidime.

2. Longitudinal analysis of resistance patterns of cultured isolates will show increasing
rates of multi-antibiotic resistance.

Adult patients over 18 years of age presenting with endophthalmitis and able to sign
consent.

Inclusion Criteria:

- all adult patients age 18 or greater presenting with bacterial endophthalmitis to the
Vanderbilt Eye Institute and who grow positive cultures

Exclusion Criteria:

- Patients < 18 years of age or those patients without positive cultures
We found this trial at
1
site
Nashville, Tennessee 37232
?
mi
from
Nashville, TN
Click here to add this to my saved trials